More bad news for troubled Point Therapeutics

With an FDA hold on its failed lead drug development program, Boston-based Point Therapeutics today announced that it is cutting its work force by 60 percent. There was no information on the number of jobs involved, but the company's statement said the workforce reduction would cost about $130,000. Several months ago, the company announced that talabostat failed to hit a primary endpoint. Later, their monitoring committee recommended that the company halt two late-stage studies of the drug. In the meantime, its stock has been beaten to a pulp and the company had already announced cuts last fall as it concentrated its efforts on the cancer front.

- read the short announcement

Related Articles:
Talabostat trial put on hold. Report
Point Therapeutics' cancer drug misses endpoint. Report
Point Therapeutics cuts staff. Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.